RegulatoryRegulatoryPHN-03182026-09-17 13:26 CT
FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
Source · FDA press releases
TLDR
The FDA announced approval of Fayuvi (rebisufligene etisparvovec-hopf), a gene therapy for pediatric patients with Sanfilippo syndrome type A. The agency describes it as the first treatment for the condition, also known as mucopolysaccharidosis type IIIA (MPS IIIA).
01—Key points
- 01The approval covers pediatric patients with MPS IIIA.
- 02The excerpt provides no clinical trial results or safety details.
- 03None of the listed peptides are mentioned.
Why it matters Editorial
The FDA announcement marks a first treatment approval for this pediatric condition, but its relevance to peptides is limited.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.